Spots Global Cancer Trial Database for recurrent acute myeloid leukemia
Every month we try and update this database with for recurrent acute myeloid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant | NCT05799079 | Recurrent Acute... | Venetoclax Decitabine Cedazuridine Bone Marrow Asp... Biospecimen Col... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | NCT05396859 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Decitabine and ... Entrectinib Laboratory Biom... | 18 Years - | OHSU Knight Cancer Institute | |
| Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | NCT01640301 | Recurrent Adult... Recurrent Child... Secondary Acute... Therapy-Related... Donor Hematopoietic C... HLA-A*0201 Posi... Recurrent Acute... | Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... WT1-Sensitized ... | - | Fred Hutchinson Cancer Center | |
| Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | NCT03009240 | Acute Myeloid L... Recurrent Acute... Refractory Acut... Secondary Acute... Therapy-Related... Untreated Adult... | Decitabine Laboratory Biom... Pevonedistat Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | NCT03969446 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Decitabine Pembrolizumab Venetoclax | 18 Years - | City of Hope Medical Center | |
| Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia | NCT03629171 | Recurrent Acute... Refractory Acut... | Liposome-encaps... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03745352 | Recurrent Acute... Refractory Acut... | Azacitidine Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | NCT03602898 | Acute Lymphobla... Acute Myeloid L... Chronic Myelomo... Chronic Phase C... Hematopoietic a... Myelodysplastic... Myelofibrosis Myeloproliferat... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Refractory Acut... Therapy-Related... | Anti-Thymocyte ... Busulfan Cyclophosphamid... Cyclosporine Fludarabine Pho... Methotrexate Peripheral Bloo... Quality-of-Life... Questionnaire A... Tacrolimus Total-Body Irra... | - 65 Years | Fred Hutchinson Cancer Center | |
| Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | NCT04146038 | Acute Myeloid L... Chronic Myelomo... Myeloblasts 10 ... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... Secondary Acute... | Azacitidine Decitabine Salsalate Venetoclax | 18 Years - | Rutgers, The State University of New Jersey | |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01892371 | FLT3 Gene Mutat... FLT3 Internal T... Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Myel... | Azacitidine Cytarabine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | NCT04487106 | Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Myel... | Azacitidine Trametinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | NCT01822509 | Allogeneic Hema... Myeloproliferat... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Chron... Recurrent Hemat... Recurrent Hodgk... Recurrent Myelo... Recurrent Non-H... Recurrent Plasm... | Ipilimumab Laboratory Biom... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation | NCT04203316 | Recurrent Acute... Refractory Acut... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Enasidenib Enasidenib Mesy... | 24 Months - 21 Years | Children's Oncology Group | |
| Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT02953561 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Avelumab Azacitidine Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT05010122 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Refractory Acut... | Decitabine and ... Gilteritinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT03813147 | Acute Myeloid L... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Azacitidine Cytarabine Fludarabine Pho... Methotrexate Pevonedistat Therapeutic Hyd... | 1 Month - 21 Years | National Cancer Institute (NCI) | |
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04047641 | Acute Myeloid L... Blasts 20 Perce... High Risk Myelo... Recurrent Acute... Recurrent Acute... Recurrent High ... Refractory Acut... Refractory High... | Cladribine Cytarabine Idarubicin Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | NCT06399640 | Relapsed Myelod... Refractory Myel... Acute Myeloid L... Recurrent Acute... Refractory Acut... | Eltanexor Venetoclax Bone Marrow Asp... Biospecimen Col... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04493164 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... | Ivosidenib Liposome-encaps... | 18 Years - | M.D. Anderson Cancer Center | |
| Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia | NCT04158739 | Recurrent Acute... Refractory Acut... | Cytarabine Flotetuzumab | - 20 Years | Children's Oncology Group | |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT03670966 | Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... Recurrent Mixed... Refractory Mixe... Hematopoietic a... | Astatine At 211... Cyclophosphamid... Total-Body Irra... Peripheral Bloo... Bone Marrow Tra... Mycophenolate M... Recombinant Gra... Fludarabine Pho... Tacrolimus Bone Marrow Asp... Biospecimen Col... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia | NCT03983824 | Recurrent Acute... Refractory Acut... | Cytarabine Etoposide Phosp... Mitoxantrone Hy... Peposertib | 18 Years - | National Cancer Institute (NCI) | |
| Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | NCT02890329 | Previously Trea... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... Secondary Acute... Secondary Myelo... | Decitabine Ipilimumab | 18 Years - | National Cancer Institute (NCI) | |
| Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT03067571 | High Risk Myelo... Recurrent Acute... Refractory Acut... | Daratumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | NCT05222984 | Recurrent Acute... Refractory Acut... | Decitabine Navitoclax Venetoclax | 16 Years - | City of Hope Medical Center | |
| A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS | NCT05456269 | Acute Myeloid L... Recurrent Acute... Refractory Acut... Higher Risk Mye... Chronic Myelomo... | Bisantrene Dihy... Bisantrene Dihy... Cytarabine Hydr... Decitabine and ... | 18 Years - | Race Oncology Ltd | |
| NK Cells in Cord Blood Transplantation | NCT01619761 | Accelerated Pha... Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Chronic Phase C... DS Stage II Pla... DS Stage III Pl... High Grade B-Ce... ISS Stage II Pl... ISS Stage III P... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Hodgk... Recurrent Non-H... Recurrent Small... Refractory Acut... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... Secondary Acute... Therapy-Related... Therapy-Related... | Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Lenalidomide Melphalan Mycophenolate M... Natural Killer ... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ... | - 75 Years | M.D. Anderson Cancer Center | |
| JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia | NCT03557970 | Recurrent Acute... Refractory Acut... | Edicotinib Pharmacokinetic... | 18 Years - | OHSU Knight Cancer Institute | |
| Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | NCT03214562 | High Risk Myelo... Recurrent Acute... Refractory Acut... | Cytarabine Filgrastim Fludarabine Idarubicin Pegfilgrastim Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML | NCT04493099 | Recurrent Acute... Refractory Acut... | Alvocidib Hydro... Decitabine Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | NCT05320380 | Recurrent Acute... Recurrent B Acu... Recurrent Mixed... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Mixe... Refractory T Ac... | Anti-CD123 ADC ... Bone Marrow Asp... Cytarabine Fludarabine Pho... Hydrocortisone ... Liposome-encaps... Methotrexate Prednisolone | 12 Months - 22 Years | Children's Oncology Group | |
| Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia | NCT03634228 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Cytarabine Milademetan Tos... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors | NCT05035706 | Acute Myeloid L... Myeloid Leukemi... Recurrent Acute... | Biopsy Biospecimen Col... Electronic Heal... Photography | 18 Years - | M.D. Anderson Cancer Center | |
| Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | NCT03009240 | Acute Myeloid L... Recurrent Acute... Refractory Acut... Secondary Acute... Therapy-Related... Untreated Adult... | Decitabine Laboratory Biom... Pevonedistat Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | NCT04146038 | Acute Myeloid L... Chronic Myelomo... Myeloblasts 10 ... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... Secondary Acute... | Azacitidine Decitabine Salsalate Venetoclax | 18 Years - | Rutgers, The State University of New Jersey | |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | NCT02220985 | Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Allogeneic Hema... Blast Phase Chr... Blastic Plasmac... Childhood Acute... Childhood Acute... Donor Lymphoblastic L... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Child... Recurrent Child... Recurrent Chron... Refractory Acut... Refractory Acut... Acute Lymphobla... Acute Myeloid L... | Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Methotrexate Mycophenolate M... Peripheral Bloo... Peripheral Bloo... Tacrolimus Thiotepa Total-Body Irra... | - 60 Years | Fred Hutchinson Cancer Center | |
| Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant | NCT02684162 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Myelo... | Donor Lymphocyt... Guadecitabine Laboratory Biom... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03874052 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Ruxolitinib Venetoclax | 18 Years - | OHSU Knight Cancer Institute | |
| Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | NCT03214562 | High Risk Myelo... Recurrent Acute... Refractory Acut... | Cytarabine Filgrastim Fludarabine Idarubicin Pegfilgrastim Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia | NCT04207190 | Recurrent Acute... Refractory Acut... | Gemtuzumab Ozog... Quality-of-Life... Questionnaire A... Talazoparib Talazoparib Tos... | 18 Years - | Roswell Park Cancer Institute | |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | NCT04375631 | Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Mixe... Refractory Myel... Refractory Acut... Refractory Acut... | Cladribine Cyclophosphamid... Cyclosporine Cytarabine Filgrastim Hematopoietic C... Mitoxantrone Mycophenolate M... Mycophenolate S... Total-Body Irra... Idarubicin Fludarabine Cytarabine Multigated Acqu... Echocardiograph... X-Ray Imaging Bone Marrow Bio... Bone Marrow Asp... | 18 Years - | Fred Hutchinson Cancer Center | |
| Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | NCT01904136 | Accelerated Pha... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... de Novo Myelody... Myelodysplastic... Recurrent Acute... Recurrent Chron... Therapy-Related... | Allogeneic Hema... Bone Marrow Tra... Cyclophosphamid... Fludarabine Laboratory Biom... Melphalan Mycophenolate M... Natural Killer ... Peripheral Bloo... Tacrolimus Total-Body Irra... | 2 Years - 65 Years | M.D. Anderson Cancer Center | |
| Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | NCT03661307 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... | Decitabine Quizartinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | NCT03683433 | Acute Bilineal ... Acute Biphenoty... Chronic Myelomo... IDH2 Gene Mutat... Myelodysplastic... Recurrent Acute... Refractory Acut... | Azacitidine Enasidenib Mesy... | 18 Years - | M.D. Anderson Cancer Center | |
| STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy | NCT03063944 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | STAT Inhibitor ... Decitabine Venetoclax Laboratory Biom... | 18 Years - | Thomas Jefferson University | |
| Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation | NCT04203316 | Recurrent Acute... Refractory Acut... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Enasidenib Enasidenib Mesy... | 24 Months - 21 Years | Children's Oncology Group | |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | NCT03683433 | Acute Bilineal ... Acute Biphenoty... Chronic Myelomo... IDH2 Gene Mutat... Myelodysplastic... Recurrent Acute... Refractory Acut... | Azacitidine Enasidenib Mesy... | 18 Years - | M.D. Anderson Cancer Center | |
| Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia | NCT04188405 | Accelerated Pha... Acute Myeloid L... Blast Phase Chr... Recurrent Acute... Recurrent Chron... Refractory Acut... Refractory Chro... | Decitabine Ponatinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | NCT05396859 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Decitabine and ... Entrectinib Laboratory Biom... | 18 Years - | OHSU Knight Cancer Institute | |
| Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia | NCT03132454 | Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... | Decitabine Dexamethasone Palbociclib Sorafenib | 15 Years - | M.D. Anderson Cancer Center | |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04493164 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... | Ivosidenib Liposome-encaps... | 18 Years - | M.D. Anderson Cancer Center | |
| Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | NCT02397720 | Acute Bilineal ... Acute Biphenoty... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Refractory Acut... Secondary Acute... Therapy-Related... | Azacitidine Ipilimumab Laboratory Biom... Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NCT04774393 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Decitabine and ... Enasidenib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | NCT03969446 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Decitabine Pembrolizumab Venetoclax | 18 Years - | City of Hope Medical Center | |
| Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant | NCT02684162 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Myelo... | Donor Lymphocyt... Guadecitabine Laboratory Biom... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia | NCT03132454 | Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... | Decitabine Dexamethasone Palbociclib Sorafenib | 15 Years - | M.D. Anderson Cancer Center | |
| Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | NCT04128748 | Acute Myeloid L... Blasts More Tha... High Risk Myelo... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Liposome-encaps... Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS | NCT05456269 | Acute Myeloid L... Recurrent Acute... Refractory Acut... Higher Risk Mye... Chronic Myelomo... | Bisantrene Dihy... Bisantrene Dihy... Cytarabine Hydr... Decitabine and ... | 18 Years - | Race Oncology Ltd | |
| Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia | NCT04250051 | Recurrent Acute... Recurrent Myelo... Recurrent Myelo... Refractory Acut... Refractory Myel... | Cytarabine Filgrastim Fludarabine Fludarabine Pho... Ivosidenib | 18 Years - | Northwestern University | |
| Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | NCT01640301 | Recurrent Adult... Recurrent Child... Secondary Acute... Therapy-Related... Donor Hematopoietic C... HLA-A*0201 Posi... Recurrent Acute... | Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... WT1-Sensitized ... | - | Fred Hutchinson Cancer Center | |
| Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | NCT03953898 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Biospecimen Col... Bone Marrow Asp... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure | NCT04905810 | Acute Myeloid L... Recurrent Acute... | Azacitidine Decitabine Venetoclax | 18 Years - | University of California, Davis | |
| Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | NCT06399640 | Relapsed Myelod... Refractory Myel... Acute Myeloid L... Recurrent Acute... Refractory Acut... | Eltanexor Venetoclax Bone Marrow Asp... Biospecimen Col... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NCT05627232 | Recurrent Acute... Refractory Acut... | Tazemetostat Liposome-encaps... Bone Marrow Asp... Biospecimen Col... Palbociclib | 18 Years - | Thomas Jefferson University | |
| Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT03772925 | Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Belinostat Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT05010122 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Refractory Acut... | Decitabine and ... Gilteritinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | NCT04752163 | Hematopoietic a... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Acut... Refractory Chro... Refractory Myel... | DS-1594b Azacitidine Cyclophosphamid... Cytarabine Dexamethasone Filgrastim Leucovorin Mesna Methotrexate Posaconazole Prednisone Rituximab Venetoclax Vincristine Voriconazole | 18 Years - | M.D. Anderson Cancer Center | |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia | NCT03128034 | Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Refractory Acut... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Mixe... Mixed Phenotype... | Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Pretargeted Rad... Total-Body Irra... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | NCT05320380 | Recurrent Acute... Recurrent B Acu... Recurrent Mixed... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Mixe... Refractory T Ac... | Anti-CD123 ADC ... Bone Marrow Asp... Cytarabine Fludarabine Pho... Hydrocortisone ... Liposome-encaps... Methotrexate Prednisolone | 12 Months - 22 Years | Children's Oncology Group | |
| Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome | NCT03672539 | Acute Myeloid L... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Acute... Refractory Acut... | Gemtuzumab Ozog... Liposome-encaps... Quality-of-Life... | 18 Years - | M.D. Anderson Cancer Center | |
| Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant | NCT03247088 | Recurrent Acute... Refractory Acut... | Allogeneic Hema... Busulfan Cyclophosphamid... Filgrastim Fludarabine Mycophenolate M... Sorafenib Tacrolimus | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | NCT04874194 | Hematopoietic a... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Acut... Refractory Myel... | Omacetaxine Mep... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | NCT04874194 | Hematopoietic a... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Acut... Refractory Myel... | Omacetaxine Mep... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | NCT02890329 | Previously Trea... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... Secondary Acute... Secondary Myelo... | Decitabine Ipilimumab | 18 Years - | National Cancer Institute (NCI) | |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome | NCT03404193 | Acute Myeloid L... Acute Myeloid L... Blastic Plasmac... Chronic Myelomo... Mixed Phenotype... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Blast... Recurrent Chron... Recurrent Mixed... Refractory Acut... Refractory Blas... Refractory Chro... Refractory Mixe... | Decitabine Laboratory Biom... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy | NCT03063944 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | STAT Inhibitor ... Decitabine Venetoclax Laboratory Biom... | 18 Years - | Thomas Jefferson University | |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | NCT03969446 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Decitabine Pembrolizumab Venetoclax | 18 Years - | City of Hope Medical Center | |
| Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NCT04975919 | Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... | Decitabine and ... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | NCT03471260 | Acute Myeloid L... Hematopoietic a... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... | Azacitidine Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | NCT04435691 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Azacitidine Magrolimab Venetoclax | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
